Investigating and addressing the immediate and long-term consequences of the COVID-19 pandemic on patients with substance use disorders: a scoping review and evidence map protocol.
COVID-19
public health
substance misuse
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
07 09 2021
07 09 2021
Historique:
entrez:
8
9
2021
pubmed:
9
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
The COVID-19 pandemic has driven unprecedented social and economic reform in efforts to curb the impact of disease. Governments worldwide have legislated non-essential service shutdowns and adapted essential service provision in order to minimise face-to-face contact. We anticipate major consequences resulting from such policies, with marginalised populations expected to bear the greatest burden of such measures, especially those with substance use disorders (SUDs). We aim to conduct (1) a scoping review to summarise the available evidence evaluating the impact of the COVID-19 pandemic on patients with SUDs, and (2) an evidence map to visually plot and categorise the current available evidence evaluating the impact of COVID-19 on patients with SUDs to identify gaps in addressing high-risk populations. Ethics approval is not required for this scoping review as we plan to review publicly available data. This is part of a multistep project, whereby we intend to use the findings generated from this review in combination with data from an ongoing prospective cohort study our team is leading, encompassing over 2000 patients with SUDs receiving medication-assisted therapy in Ontario prior to and during the COVID-19 pandemic.
Identifiants
pubmed: 34493506
pii: bmjopen-2020-045946
doi: 10.1136/bmjopen-2020-045946
pmc: PMC8424417
doi:
Substances chimiques
Mitomycin
50SG953SK6
Doxorubicin
80168379AG
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e045946Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Addict Nurs. 2018 Apr/Jun;29(2):78-83
pubmed: 29864054
Ann Intern Med. 2020 Jul 7;173(1):59-60
pubmed: 32240291
Syst Rev. 2016 Feb 10;5:28
pubmed: 26864942
Pain Physician. 2016 May;19(4):215-28
pubmed: 27228510
Lancet Public Health. 2020 May;5(5):e259
pubmed: 32277874
Biol Sex Differ. 2015 Nov 10;6:21
pubmed: 26557977
Schizophr Bull. 2009 Mar;35(2):383-402
pubmed: 19011234
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Am J Drug Alcohol Abuse. 1987;13(1-2):59-71
pubmed: 3687885
Drug Alcohol Depend. 2015 Apr 1;149:1-9
pubmed: 25702934
J Clin Epidemiol. 2016 Nov;79:120-129
pubmed: 27387966
Ann Intern Med. 2020 Jul 7;173(1):61-62
pubmed: 32240293
Trials. 2020 Jan 6;21(1):30
pubmed: 31907000
Milbank Q. 2009 Jun;87(2):495-534
pubmed: 19523126
Br J Anaesth. 2020 Oct;125(4):e382-e383
pubmed: 32768181
Ann Intern Med. 2020 Jul 7;173(1):57-58
pubmed: 32240283
Sci Rep. 2014 Aug 26;4:6189
pubmed: 25155550
Addiction. 2008 Jan;103(1):119-25
pubmed: 18028521
Am J Drug Alcohol Abuse. 1987;13(1-2):33-57
pubmed: 3318399
Am J Drug Alcohol Abuse. 1987;13(3):231-51
pubmed: 3687889
CMAJ Open. 2015 Jul 17;3(3):E344-51
pubmed: 26457294
Drug Alcohol Depend. 2015 Apr 1;149:31-9
pubmed: 25682479